Business
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal. The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 i
About this update from Greenwich Lifesciences, Inc.
[{"type":"image","alt":"Greenwich LifeSciences, Inc.","displaySize":"","headline":null,"caption":"Greenwich LifeSciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/5236cbdf62d9160f7f17a269e6a93fa7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CdB3UijgWjtUF2S9KALplg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5236cbdf62d9160f7f17a269e6a93fa7","width":300,"height":123}},"lazy":false},{"type":"text","content":"STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal.","length":377,"tagName":"p"},{"type":"text","content":"The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition to Spain, France, Germany, Italy, Poland, Romania, Ireland, and the US.","length":218,"tagName":"p"},{"type":"text","content":"According to the latest data collected by the European Cancer Information System (click here), a total of 9,065 new cases of breast cancer were diagnosed in Portugal in 2022, which is the most common cancer diagnosed in women, representing approximately 30% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Portugal with 2,211 deaths in 2022.","length":386,"tagName":"p"},{"type":"text","content":"Luís António Marques da Costa, MD, PhD, will be serving as the national principal investigator in Portugal for FLAMINGO-01. Dr. Costa is an Associate Professor of Medicine, Oncology & Oncobiology, FML-UL, Lisbon, Portugal, and Head of the Clinical Translational Oncology Research Unit at the Institute of Molecular Medicine. He has also served as Director of the Oncology Department at Hospital de Santa Maria in Lisbon since 2005. At the School of Medicine, he is the Coordinator Professor of "Oncobiologia" a new teaching unit that aims to teach the understanding of clinical oncology through molecular medicine. He is involved in multiple clinical trials i...